The Washington Post

Indian drugmaker Ranbaxy recalls more than 64,000 bottles of its generic version of Lipitor

— Indian drugmaker Ranbaxy Laboratories, reeling under a flurry of regulatory rebukes over manufacturing quality concerns, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after a doseage mix-up.

Ranbaxy recalled tablets of atorvastatin calcium, the generic version of Pfizer’s cholesterol-fighter Lipitor, after a pharmacist found a 20 milligram tablet in a sealed bottle marked for 10 milligram tablets, the U.S. Food and Drug Administration said on its Web site.

Ranbaxy, India’s biggest drugmaker by revenue and majority-owned by Japan’s Daiichi Sankyo, confirmed the recall of select batches of the drug but said the company had not received any product complaints.

“Ranbaxy is proactively recalling the lots out of an abundance of caution, keeping the safety of its patients in mind and with the full knowledge of the U.S. FDA,” the company said in a statement issued to the Reuters news agency Saturday.

The recall is the latest in a series of problems to hit Ranbaxy, which has had all its factories in India stopped from sending drugs and ingredients to the United States, its biggest market.

Ranbaxy-owned Ohm Laboratories in New Jersey is now the company’s only permitted maker of drugs for U.S. sale.

Worries about quality control in India’s $14 billion drug industry have come to the fore in the past year as plants run by Ranbaxy and local rival Wockhardt have been banned after falling short of the FDA’s “good manufacturing practices.”

India’s drugmakers have come under closer scrutiny as the FDA, the guardian of the world’s most important pharmaceuticals market, has increased its presence in the country, reflecting India’s growing importance as a supplier to the United States.

Indian generic drugmakers such as Ranbaxy, Wockhardt and Dr. Reddy’s Laboratories produce nearly 40 percent of generic drugs and over-the-counter products and 10 percent of finished dosages used in the United States.

The FDA declared the recall of Lipitor generic by Ranbaxy as Class II, which signifies a remote chance of severe adverse consequences or death due to the product flaw.

This is not the first time the company has recalled the drug.

In November 2012, Ranbaxy recalled certain lots of the widely used cholesterol-lowering medicine after it discovered contamination with tiny particles of glass.

Ranbaxy stopped manufacturing the blockbuster drug while it sought to fix the problems that led to the recall. It resumed production for sale in the United States in February last year.

Last month, the FDA prohibited Ranbaxy from shipping to the United States any pharmaceutical ingredient made at its Toansa plant in northern India following an inspection that found poor manufacturing practices.

The ban, which followed similar actions at two plants in 2008 and another in September 2013, has triggered scrutiny by FDA counterparts in other countries, including in India.

Ranbaxy shares have lost 18 percent this year, compared with a 4 percent gain for India’s National Stock Exchange index.

— Reuters


Success! Check your inbox for details. You might also like:

Please enter a valid email address

See all newsletters

Show Comments
Most Read


Success! Check your inbox for details.

See all newsletters

Your Three. Videos curated for you.
Play Videos
Sleep advice you won't find in baby books
In defense of dads
Scenes from Brazil's Carajás Railway
Play Videos
For good coffee, sniff, slurp and spit
How to keep your child safe in the water
How your online data can get hijacked
Play Videos
How to avoid harmful chemicals in school supplies
Full disclosure: 3 bedrooms, 2 baths, 1 ghoul
How much can one woman eat?
Play Videos
What you need to know about Legionnaires' disease
How to get organized for back to school
Pandas, from birth to milk to mom

To keep reading, please enter your email address.

You’ll also receive from The Washington Post:
  • A free 6-week digital subscription
  • Our daily newsletter in your inbox

Please enter a valid email address

I have read and agree to the Terms of Service and Privacy Policy.

Please indicate agreement.

Thank you.

Check your inbox. We’ve sent an email explaining how to set up an account and activate your free digital subscription.